



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<div><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)</div> <div></div>		Application Number	10/596,997
		I.A. Filing Date	July 5, 2006
		First Named Inventor	Stephen Gillies
		Group Art Unit	1645
		Examiner Name	Not Yet Assigned
Sheet 1 of 18	Attorney Docket Number	ANTBH/P31763US	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		4,440,859		Rutter, et al.	04-03-1984	
		4,469,797		Albarella	09-04-1984	
		4,530,901		Weissmann	07-23-1985	
		4,582,800		Crowl	04-15-1986	
		4,677,063		Mark, et al.	06-30-1987	
		4,678,751		Goeddel	07-07-1987	
		4,704,362		Itakura, et al.	11-03-1987	
		4,710,463		Murray	12-01-1987	
		4,757,006		Toole, Jr., et al.	07-12-1988	
		4,766,075		Goeddel, et al.	08-23-1988	
		4,810,648		Stalker	03-07-1989	
		5,019,368		Epstein, et al.	05-28-1991	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		EP	0 239 400		Gregory Paul Winter	09-30-1987		
		EP	0 251 744		Delta Biotechnology, Ltd.	01-07-1988		
		EP	0 258 067		Delta Biotechnology, Ltd.	03-02-1988		
		EP	0 344 134		Ist. Naz. Ric. Sul. Cancro.	11-29-1989		
		EP	0 350 230		Res. Dev. Foundation	01-10-1990		
		EP	0 375 562		Oncogen	06-27-1990		
		EP	0 396 387		Res. Dev. Foundation	11-07-1990		

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<div>Substitute for form 1449A/PTO</div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>				Complete if Known	
				Application Number	10/596,997
				I.A. Filing Date	July 5, 2006
				First Named Inventor	Stephen Gillies
				Group Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	2	of	18	Attorney Docket Number	ANTBH/P31763US

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		5,073,627		Curtis, et al.	12-17-1991	
		5,199,942		Gillies	04-06-1993	
		5,349,053		Landolfi	09-20-1994	
		5,457,038		Trinchieri, et al.	10-10-1995	
		5,480,981		Goodwin, et al.	01-02-1996	
		5,609,846		Goldenberg	03-11-1997	
		5,614,184		Sytowski, et al.	03-25-1997	
		5,650,150		Gillies	07-22-1997	
		5,650,492		Gately, et al.	07-22-1997	
		5,709,859		Aruffo, et al.	01-30-1998	
		5,728,552		Fujisawa, et al.	03-17-1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		EP	0 433 827		Hoffman La Roche	06-26-1991		
		EP	0 706 799		Merck Patent GmbH	04-17-1996		
		EP	0 790 309		Hoffman La Roche	08-20-1997		
		PCT	WO 88/00052		Dartmouth College	01-14-1988		
		PCT	WO 89/02922		Genentech, Inc.	04-06-1989		
		PCT	WO 90/01063		Delta Biotechnology, Ltd.	02-08-1990		

Examiner's Signature		Date Considered	
-------------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	
				10/596,997	
				I.A. Filing Date	
				July 5, 2006	
				First Named Inventor	
Stephen Gillies					
Group Art Unit					
1645					
Examiner Name					
Not Yet Assigned					
Sheet	3	of	18	Attorney Docket Number	
				ANTBH/P31763US	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		5,858,347		Bauer, et al.	01-12-1999	
		5,891,680		Lieschke, et al.	04-06-1999	
		5,922,685		Rakhmievich, et al.	07-13-1999	
		5,994,104		Anderson, et al.	11-30-1999	
		6,086,875		Blumberg, et al.	07-11-2000	
		6,169,070		Chen, et al.	01-02-2001	
		6,335,176		Inglese, et al.	01-01-2002	
		6,444,792		Gray, et al.	09-03-2002	
		6,485,726		Blumberg, et al.	11-26-2002	
		6,500,641		Chen, et al.	12-31-2002	
		6,551,592		Lindhofer, et al.	04-22-2003	
		6,620,413		Sauvage, et al.	09-16-2003	
		6,750,329		Rosenblum, et al.	06-15-2004	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		PCT	WO 91/00360		Medarex, Inc.	01-10-1991		
		PCT	WO 91/14438		University of Columbia	10-03-1991		
		PCT	WO 95/21258		U.S. Government	08-10-1995		
		PCT	WO 95/31483		Eclagen, Ltd.	11-23-1995		
		PCT	WO 96/04388		Smithkline Beecham, PLC	02-15-1996		

Examiner's Signature		Date Considered	
-------------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/596,997
				I.A. Filing Date	July 5, 2006
				First Named Inventor	Stephen Gillies
				Group Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	4	of	18	Attorney Docket Number	ANTBH/P31763US

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		2001/0053539		Lauffer, et al.	12-20-2001	
		2002/0142374		Gallo, et al.	10-03-2002	
		2002/0192222		Blumberg, et al.	12-19-2002	
		2003/0012789		Blumberg, et al.	01-16-2003	
		2004/0013640		Zardi, et al.	01-22-2004	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		PCT	WO 96/18412		Beth Israel Hospital	06-20-1996		
		PCT	WO 96/40792		Novonordisk AS	12-19-1996		
		PCT	WO 97/00319		Smithkline Beecham, PLC	01-03-1997		
		PCT	WO 97/20062		University of Massachusetts	06-05-1997		
		PCT	WO 97/24440		Genentech, Inc.	07-10-1997		
		PCT	WO 97/33617		Protein Design Labs, Inc.	09-18-1997		
		PCT	WO 97/33619		QLT Phototherapeutics, Inc.	09-18-1997		
		PCT	WO 97/43316		Beth Israel Hospital	11-20-1997		
		PCT	WO 98/00127		Univ. Bar Ilan	01-08-1998		
		PCT	WO 98/28427		Amgen, Inc.	07-02-1998		
		PCT	WO 98/30706		Alliance Pharma	07-16-1998		
		PCT	WO 98/46257		Amgen, Inc.	10-22-1998		
		PCT	WO 99/02709		Beth Israel Hospital	01-21-1999		


Examiner's Signature		Date Considered	
-------------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<div>Substitute for form 1449A/PTO</div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>				Complete if Known	
				Application Number	
				10/596,997	
				I.A. Filing Date	
				July 5, 2006	
				First Named Inventor	
Stephen Gillies					
Group Art Unit					
1645					
Examiner Name					
Not Yet Assigned					
Sheet	5	of	18	Attorney Docket Number	
				ANTBH/P31763US	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		PCT	WO 99/29732		Lexigen Pharm Corp	06-17-1999		
		PCT	WO 99/43713		Lexigen Pharm Corp	09-02-1999		
		PCT	WO 99/52562		Lexigen Pharm Corp	10-21-1999		
		PCT	WO 99/53958		Lexigen Pharm Corp	10-28-1999		
		PCT	WO 00/11033		Lexigen Pharm Corp	03-02-2000		
		PCT	WO 00/40615		Lexigen Pharm Corp	07-13-2000		
		PCT	WO 00/69913		Lexigen Pharm Corp	11-23-2000		
		PCT	WO 01/07081		Lexigen Pharm Corp	02-01-2001		
		PCT	WO 01/36489		Merck Patent GmbH	05-25-2001		
		PCT	WO 01/58957		Lexigen Pharm Corp	08-16-2001		
		PCT	WO 02/02143		Lexigen Pharm Corp	01-10-2002		
		PCT	WO 02/066514		Lexigen Pharm Corp	08-29-2002		
		PCT	WO 02/072605		Lexigen Pharm Corp	09-19-2002		
		PCT	WO 02/090566		Lexigen Pharm Corp	11-14-2002		
		PCT	WO 03/015697		Univ. Southern California	02-27-2003		
		PCT	WO 03/048334		EMD Lexigen Res. CT Corp.	06-12-2003		
		PCT	WO 03/076469		Philogen SRL; Schering AG	09-18-2003		
		PCT	WO 03/077834		Brigham and Women's Hospital	09-25-2003		
		PCT	WO 03/093478		Molmed SPA	11-13-2003		


Examiner's Signature		Date Considered	
-------------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	
				10/596,997	
				I.A. Filing Date	
				July 5, 2006	
				First Named Inventor	
Stephen Gillies					
Group Art Unit					
1645					
Examiner Name					
Not Yet Assigned					
Sheet	6	of	18	Attorney Docket Number	
				ANTBH/P31763US	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		AFONSO, et al., "The adjuvant effect of interleukin-12 in a vaccine against Leishmania major", <i>Science</i> , 263(5144):235-7 (1994).	
		ANSELL, et al., "Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma", <i>Blood</i> , 99(1):67-74 (2002).	
		BARBULESCU, et al., "IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes", <i>J. Immunol.</i> , 160(8):3642-7 (1998).	
		BEGGS, "Transformation of yeast by a replicating hybrid plasmid", <i>Nature</i> , 275(5676):104-9 (1978).	
		BERENT, et al., "Comparison of oligonucleotide and long DNA fragments as probes in DNA and RNA dot, southern, northern, colony and plaque hybridizations", <i>Biotechniques</i> , 3:208-220 (1985).	
		BETTER, et al., " <i>Escherichia coli</i> secretion of an active chimeric antibody fragment", <i>Science</i> , 240(4855):1041-3 (1988).	
		BIRD, et al., "Single-chain antigen-binding proteins", <i>Science</i> , 242(4877):423-6 (1988).	
		BITONTI, et al., "Transepithelial absorption of an erythropoietin-Fc fusion protein after delivery to the central airways", <i>Respiratory Drug Delivery</i> , 8:308-312 (2002).	
		BOSHART, et al., "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus", <i>Cell</i> , 41(2):521-30 (1985).	
		CARNEMOLLA, et al., "A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors", <i>J. Cell Biol.</i> , 108(3):1139-1148 (1989).	
		CARNEMOLLA, et al., "The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence", <i>J. Biol. Chem.</i> , 267(34):24689-92 (1992).	


Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<div>Substitute for form 1449A/PTO</div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>				Complete if Known	
				Application Number	10/596,997
				I.A. Filing Date	July 5, 2006
				First Named Inventor	Stephen Gillies
				Group Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	7	of	18	Attorney Docket Number	ANTBH/P31763US

OTHER ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
		CHAN, "Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers", <i>J. Exp. Med.</i> , 173(4):869-79 (1991).		
		CHEN, et al., "Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer", <i>J. Immunol.</i> , 159(1):351-9 (1997).		
		COHEN, et al., "Nonchromosomal antibiotic resistance in bacteria: genetic transformation of <i>Escherichia coli</i> by R-factor DNA", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 69(8):2110-4 (1972).		
		COLOMBO, et al., "Amount of interleukin 12 available at the tumor site is critical for tumor regression", <i>Cancer Res.</i> , 56(11):2531-4 (1996).		
		D'ANDREA, et al., "Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells", <i>J. Exp. Med.</i> , 176(5):1387-98 (1992).		
		DESAI, et al., "IL-12 receptor. II. Distribution and regulation of receptor expression", <i>J. Immunol.</i> , 148(10):3125-32 (1992).		
		DICKERSON, et al., Proceedings of the American Association for Cancer Research Annual Meeting No. 41, page 798, abstract no. 5074 (2000).		
		DORAN, et al., "Expression of ED-B fibronectin in renal carcinoma and metastatic melanoma and targeted therapy with AS1409, a potent immunocytokine", Abstract presentation 5 <sup>th</sup> <i>Int. Congress on Targeted Therapies in Cancer</i> , NY (2006).		
		EMTAGE, et al., "Generating potent Th1/Tc1 T cell adoptive immunotherapy doses using human IL-12: Harnessing the immunomodulatory potential of IL-12 without the in vivo-associated toxicity", <i>J. Immunother.</i> , 26(2):97-106 (2003).		
		FFRENCH-CONSTANT, et al., "Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat", <i>J. Cell Biol.</i> , 109(2):903-14 (1989).		
		GATELY, et al., "The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses", <i>Annu. Rev. Immunol.</i> , 16:495-521 (1998).		


Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/596,997
				I.A. Filing Date	July 5, 2006
				First Named Inventor	Stephen Gillies
				Group Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	8	of	18	Attorney Docket Number	ANTBH/P31763US

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		GILLESSEN, et al., "Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist", <i>Eur. J. Immunol.</i> , 25(1):200-6 (1995).	
		GILLIES, et al., "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases", <i>J. Immunol.</i> , 160(12):6195-203 (1998).	
		GILLIES, et al., "Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis", <i>Clin. Cancer Res.</i> , 8(1):210-6 (2002).	
		GOLLOB, et al., "Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response", <i>Clin. Cancer Res.</i> , 6(5):1678-92 (2000).	
		GUBLER and PRESKY, "Molecular biology of interleukin-12 receptors", <i>Ann. N.Y. Acad. Sci.</i> , 795:36-40 (1996).	
		HALIN, et al., "Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature", <i>Nat. Biotechnol.</i> , 20(3):264-9 (2002).	
		HALIN, "Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha", <i>Cancer Res.</i> , 63(12):3202-10 (2003).	
		HASHIMOTO, et al., "Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively", <i>J. Immunol.</i> , 163(2):583-9 (1999).	
		HEINZEL, et al., "In vivo production and function of IL-12 p40 homodimers", <i>J. Immunol.</i> , 158(9):4381-8 (1997).	
		HEINZERLING, et al., "Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice", <i>Exp. Dermatol.</i> , 11(3):232-40 (2002).	
		HOOGENBOOM, et al, "Construction and expression of antibody-tumor necrosis factor fusion proteins", <i>Mol. Immunol.</i> , 28(9):1027-37 (1991).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.







Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<div>Substitute for form 1449A/PTO</div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>				Complete if Known	
				Application Number	
				10/596,997	
				I.A. Filing Date	
				July 5, 2006	
				First Named Inventor	
Stephen Gillies					
Group Art Unit					
1645					
Examiner Name					
Not Yet Assigned					
Sheet	9	of	18	Attorney Docket Number	
				ANTBH/P31763US	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		HOOGENBOOM, et al., "Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule", <i>Biochim. Biophys. Acta.</i> , 1096(4):345-54 (1991).	
		HUANG, et al., "Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature", <i>Science</i> , 275(5299):547-50 (1997).	
		HUSTON, et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 85(16):5879-83 (1988).	
		IWASAKI, et al., "A critical role for IL-12 in CCR5 induction on T cell receptor-triggered mouse CD4(+) and CD8(+) T cells", <i>Eur. J. Immunol.</i> , 31(8):2411-20 (2001).	
		JONES, et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse", <i>Nature</i> , 321(6069):522-5 (1986).	
		JONES, et al., "The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection", <i>J. Interferon Cytokine Res.</i> , 24(9):560-72 (2004).	
		JONES, et al., "Production of an IgG1-IL12 fusion protein", presentation at <i>Optimizing Cell Culture Development</i> (2006).	
		KANG, et al., "Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study", <i>Hum. Gene Ther.</i> , 12(6):671-84 (2001).	
		KIM, "An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production", <i>J. Immunol.</i> , 158(9):4137-44 (1997).	
		KING, et al., "Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients", <i>J. Clin. Oncol.</i> , 22(22):4463-73 (2004).	
		KO, et al., "Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer", <i>J. Immunother.</i> , 27(3):232-9 (2004)	


Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<div>Substitute for form 1449A/PTO</div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>				Complete if Known	
				Application Number	10/596,997
				I.A. Filing Date	July 5, 2006
				First Named Inventor	Stephen Gillies
				Group Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	10	of	18	Attorney Docket Number	ANTBH/P31763US

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		KOZAK, "Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin <i>in vivo</i> ", <i>Nature</i> , 308(5956):241-6 (1984).	
		LADELL, et al., "A combination of plasmid DNAs encoding murine fetal liver kinase 1 extracellular domain, murine interleukin-12, and murine interferon-gamma inducible protein-10 leads to tumor regression and survival in melanoma-bearing mice", <i>J. Mol. Med.</i> , 81(4):271-8 (2003).	
		LEBERTHON, et al., "Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate", <i>Cancer Res.</i> , 51(10):2694-8 (1991).	
		LI, et al., "Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy", <i>J. Natl. Cancer Inst.</i> , 94(10):762-8 (2002).	
		LI, et al. "Candidate genes associated with tumor regression mediated by intratumoral IL-12 electroporation gene therapy", <i>Mol. Ther.</i> , 9(3):347-54 (2004).	
		LIESCHKE, et al., "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity <i>in vivo</i> ", <i>Nat. Biotechnol.</i> , 15(1):35-40 (1997).	
		LINSLEY, et al., "CTLA-4 is a second receptor for the B cell activation antigen B7", <i>J. Exp. Med.</i> , 174(3):561-9 (1991).	
		LIU, et al., "Hormone conjugated with antibody to CD3 mediates cytotoxic T cell lysis of human melanoma cells", <i>Science</i> , 239(4838):395-8 (1988).	
		LO, et al., "High level expression and secretion of Fc-X fusion proteins in mammalian cells", <i>Protein Eng.</i> , 11(6):495-500 (1998).	
		LO, et al., "Engineering a pharmacologically superior form of leptin for the treatment of obesity", <i>Protein Eng. Des. Sel.</i> , 18(1):1-10 (2005).	
		LO, et al., "Targeted delivery of IL12 via a pan-tumor-specific antibody" (2005).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/596,997
				I.A. Filing Date	July 5, 2006
				First Named Inventor	Stephen Gillies
				Group Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	11	of	18	Attorney Docket Number	ANTBH/P31763US

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		LO, et al., "huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models", <i>Cancer Immunol. Immunother.</i> , 56(4):447-57 (2007).	
		LODE, et al., "Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow", <i>J. Natl. Cancer Inst.</i> , 89(21):1586-94 (1997).	
		LODE, et al., "Immunocytokines: a promising approach to cancer immunotherapy", <i>Pharmacol. Ther.</i> , 80(3):277-92 (1998).	
		LODE, et al., "Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy", <i>Blood</i> , 91(5):1706-15 (1998).	
		LODE, et al., "Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 95(5):2475-80 (1998).	
		LODE, et al., "Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 96(4):1591-6 (1999).	
		LODE, et al., "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 96(15):8591-6 (1999).	
		LODE, et al., "Amplification of T cell-mediated immune responses by antibody-cytokine fusion proteins", <i>Immunol. Invest.</i> , 29(2):117-20 (2000).	
		LODE, et al., "Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction", <i>J. Clin. Invest.</i> , 105(11):1623-30 (2000).	
		LODE, et al., "What to do with targeted IL-2", <i>Drugs Today (Barc)</i> , 36(5):321-36 (2000).	
		LOTZE, et al., "Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials", <i>Ann. N.Y. Acad. Sci.</i> , 795:440-54 (1996).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	
				10/596,997	
				I.A. Filing Date	
				July 5, 2006	
				First Named Inventor	
Stephen Gillies					
Group Art Unit					
1645					
Examiner Name					
Not Yet Assigned					
Sheet	12	of	18	Attorney Docket Number	
				ANTBH/P31763US	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		MAGHAZACHI, et al., "Interferon-inducible protein-10 and lymphotactin induce the chemotaxis and mobilization of intracellular calcium in natural killer cells through pertussis toxin-sensitive and -insensitive heterotrimeric G-proteins", <i>FASEB J.</i> , 11(10):765-74 (1997).	
		MAJEWSKI, et al., "Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo", <i>J. Invest. Dermatol.</i> , 106(5):1114-8 (1996).	
		MANDPE, et al., "Cure of an established nonimmunogenic tumor, SCC VII, with a novel interleukin 12-based immunotherapy regimen in C3H mice", <i>Arch. Otolaryngol. Head Neck Surg.</i> , 129(7):786-92 (2003).	
		MARIANI, et al., "Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants", <i>Cancer</i> , 80(12 Suppl):2378-84 (1997).	
		MARK, et al., "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins. Effects of mutations in the potential proteolytic cleavage site on processing and ligand binding", <i>J. Biol. Chem.</i> , 267(36):26166-71 (1992).	
		MARTINOTTI, et al., "CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes", <i>Eur. J. Immunol.</i> , 25(1):137-46 (1995).	
		MASIERO, et al., "New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12", <i>Angiogenesis</i> , 1(1):23-35 (1997).	
		MAZZOLINI, et al., "Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12", <i>Cancer Gene Ther.</i> , 6(6):514-22 (1999).	
		MEHROTRA, et al., "Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes", <i>J. Immunol.</i> , 151(5):2444-52 (1993).	
		MIDULLA, et al., "Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells", <i>Cancer Res.</i> , 60(1):164-9 (2000).	
		MORRISON, et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 81(21):6851-5 (1984).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.







Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/596,997
				I.A. Filing Date	July 5, 2006
				First Named Inventor	Stephen Gillies
				Group Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	13	of	18	Attorney Docket Number	ANTBH/P31763US

OTHER ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner's Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T <sup>2</sup>
		MOSMANN, et al., "TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties", <i>Annu. Rev. Immunol.</i> , 7:145-73 (1989).		
		MULLINS, et al., "Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation", <i>Immunopharmacol. Immunotoxicol.</i> , 20(4):473-92 (1998).		
		NARAMURA, et al., "Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells", <i>Immunol. Lett.</i> , 39(1):91-9 (1993).		
		NIETHAMMER, et al., "Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma", <i>Cancer Res.</i> , 61(16):6178-84 (2001).		
		O'SULLIVAN, et al., "Comparison of two methods of preparing enzyme-antibody conjugates: application of these conjugates for enzyme immunoassay", <i>Anal. Biochem.</i> , 100(1):100-8 (1979).		
		PALUCKA, et al., "Dendritic cells as the terminal stage of monocyte differentiation", <i>J. Immunol.</i> , 160(9):4587-95 (1998).		
		PANCOOK, et al., "Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2", <i>Cancer Immunol. Immunother.</i> , 42(2):88-92 (1996).		
		PARIHAR, et al., "IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells", <i>J. Clin. Invest.</i> , 110(7):983-92 (2002).		
		PARIHAR, et al., "A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients", <i>Clin. Cancer Res.</i> , 10(15):5027-37 (2004).		
		PARK, et al., "CD28 costimulation is required not only to induce IL-12 receptor but also to render janus kinases/STAT4 responsive to IL-12 stimulation in TCR-triggered T cells", <i>Eur. J. Immunol.</i> , 31(5):1456-64 (2001).		
		PEDLEY, et al., "Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent", <i>Cancer Res.</i> , 59(16):3998-4003 (1999).		


Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	
				10/596,997	
				I.A. Filing Date	
				July 5, 2006	
				First Named Inventor	
Stephen Gillies					
Group Art Unit					
1645					
Examiner Name					
Not Yet Assigned					
Sheet	14	of	18	Attorney Docket Number	
				ANTBH/P31763US	


OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		PENG, et al., "Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3)", <i>J. Interferon Cytokine Res.</i> , 21(9):709-20 (2001).	
		PEREZ, et al., "Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies", <i>J. Exp. Med.</i> , 163(1):166-78 (1986).	
		PERUSSIA, et al., "Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells", <i>J. Immunol.</i> , 149(11):3495-502 (1992).	
		PORTIELJE, et al., "Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant", <i>Cancer Immunol. Immunother.</i> , 54(1):37-43 (2005).	
		PUTZER, et al., "Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 94(20):10889-94 (1997).	
		RAKHMILEVICH, et al., "Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody", <i>Mol. Cancer Ther.</i> , 3(8):969-76 (2004).	
		REISFELD, et al., "Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy", <i>J. Clin. Lab Anal.</i> , 10(3):160-6 (1996).	
		REISFELD, et al., "Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein", <i>Cancer Res.</i> , 56(8):1707-12 (1996).	
		REISFELD, et al., "Recombinant antibody fusion proteins for cancer immunotherapy", <i>Curr. Top. Microbiol. Immunol.</i> , 213 (Pt 3):27-53 (1996).	
		REISFELD, et al., "Immunocytokines: a new approach to immunotherapy of melanoma", <i>Melanoma Res.</i> , 7 Suppl 2:S99-106 (1997).	
		RIECHMANN, et al., "Reshaping human antibodies for therapy", <i>Nature</i> , 332(6162):323-7 (1988).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/596,997
				I.A. Filing Date	July 5, 2006
				First Named Inventor	Stephen Gillies
				Group Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	15	of	18	Attorney Docket Number	ANTBH/P31763US

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		ROSENBERG, "Immunotherapy of cancer using interleukin 2: current status and future prospects", <i>Immunol. Today</i> , 9(2):58-62 (1988).	
		RUEHLMANN, et al. "MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma", <i>Cancer Res.</i> , 61(23):8498-503 (2001).	
		SABZEVARI, et al., "A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 91(20):9626-30 (1994).	
		SAIKI, et al., "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase", <i>Science</i> , 239(4839):487-91 (1988).	
		SAMBROOK, et al., <i>Molecular Cloning, A Laboratory Manual</i> , pp. 1.74-1.84 (1989).	
		SAVAGE, et al., "A recombinant single chain antibody interleukin-2 fusion protein", <i>Br. J. Cancer</i> , 67(2):304-10 (1993).	
		SCHNEE, et al, "Construction and expression of a recombinant antibody-targeted plasminogen activator", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 84(19):6904-8 (1987).	
		SCHOENHAUT, et al., "Cloning and expression of murine IL-12", <i>J. Immunol.</i> , 148(11):3433-40 (1992).	
		SETER, et al., "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 85(13):4842-6 (1988).	
		SHIN, et al., "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: potential applications for cellular targeting", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 87(14):5322-6 (1990).	
		SKERRA, et al., "Assembly of a functional immunoglobulin Fv fragment in <i>Escherichia coli</i> ", <i>Science</i> , 240(4855):1038-41 (1988).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<div>Substitute for form 1449A/PTO</div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>				Complete if Known	
				Application Number	10/596,997
				I.A. Filing Date	July 5, 2006
				First Named Inventor	Stephen Gillies
				Group Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	16	of	18	Attorney Docket Number	ANTBH/P31763US

OTHER ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T <sup>2</sup>
		SOUTHERN, "Detection of specific sequences among DNA fragments separated by gel electrophoresis", <i>J. Mol. Biol.</i> , 98(3):503-17 (1975).		
		TAKAHARA, et al., "The ompA signal peptide directed secretion of Staphylococcal nuclease A by <i>Escherichia coli</i> ", <i>J. Biol. Chem.</i> , 260(5):2670-4 (1985).		
		THORPE, et al., "The first international conference on vascular targeting: meeting overview", <i>Cancer Res.</i> , 63(5):1144-7 (2003).		
		TURNER, et al., "Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application", <i>J. Immunol. Methods</i> , 223(1):1-15 (1999).		
		TILL, et al., "An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins", <i>Cancer Res.</i> , 48(5):1119-23 (1988).		
		TILL, et al., "HIV-infected cells are killed by rCD4-ricin A chain", <i>Science</i> , 242(4882):1166-8 (1988).		
		TRINCHIERI, "Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes", <i>Blood</i> , 84(12):4008-27 (1994).		
		VAN HERPEN, et al., "Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor", <i>Clin. Cancer Res.</i> , 11(5):1899-909 (2005).		
		VAN VLIET, et al., "Distribution of fibronectin isoforms in human renal disease", <i>J. Pathol.</i> , 193(2):256-62 (2001).		
		VERHOEYEN, et al., "Reshaping human antibodies: grafting an antilysozyme activity", <i>Science</i> , 239(4847):1534-6 (1988).		
		VERMA, et al., "Targeted delivery of IL12 via an antibody for tumor and tmoral angiogenesis" (2006).		

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.







Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/596,997
				I.A. Filing Date	July 5, 2006
				First Named Inventor	Stephen Gillies
				Group Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	17	of	18	Attorney Docket Number	ANTBH/P31763US

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		VITI, et al., "Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis", <i>Cancer Res.</i> , 59(2):347-52 (1999).	
		VOGEL, et al., "Direct binding of IL-12 to human and murine B lymphocytes", <i>Int. Immunol.</i> , 8(12):1955-62 (1996).	
		WADLER, et al., "A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96", <i>Gynecol. Oncol.</i> , 92(3):957-64 (2004).	
		WARD, et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ", <i>Nature</i> , 341(6242):544-6 (1989).	
		WIGGINTON, et al., "Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene	
		WILLIAMS, et al., "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment", <i>Gene</i> , 43(3):319-24 (1986).	
		WINTER and MILSTEIN, "Man-made antibodies", <i>Nature</i> , 349(6307):293-9 (1991).	
		WOOLEY, et al., "Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice", <i>J. Immunol.</i> , 151(11):6602-7 (1993).	
		XIANG, et al., "Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy", <i>Cancer Res.</i> , 57(21):4948-55 (1997).	
		YAMAZAKI, et al., "Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12", <i>Gene Ther.</i> , 9(1):64-74 (2002).	
		YOUNG, et al., "Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond", <i>FEBS Lett.</i> , 377(2):135-9 (1995).	


Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<div>Substitute for form 1449A/PTO</div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>				Complete if Known	
				Application Number	10/596,997
				I.A. Filing Date	July 5, 2006
				First Named Inventor	Stephen Gillies
				Group Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	18	of	18	Attorney Docket Number	ANTBH/P31763US

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		ZAGOZDZON, et al., "Potentiation of antitumor effects of IL-12 in combination with paclitaxel in murine melanoma model <i>in vivo</i> ", <i>Int. J. Mol. Med.</i> , 4(6):645-8 (1999).	
		ZHENG, et al., "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation", <i>J. Immunol.</i> , 154(10):5590-600 (1995).	
		ZHU, et al., "Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor", <i>Invest. New Drugs</i> , 17(3):195-212 (1999).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

